Get the Weekly Intelligence Brief — top committee picks every Sunday.
GILD · NASDAQ · STOCK

Gilead Sciences (GILD) Stock Analysis

Healthcare Updated October 10, 2026
$151.17
52W $114.02 – $157.29
53/100
$187.44B
-58.1
0.33
AI Committee Verdict
Watch
53/100
Conviction: Contested · 40% agreement · 5 analysts
+4.0%
-15.6%
0.26:1
Contested

Is GILD Bullish or Bearish?

Mixed. Innellis AI committee rates Gilead Sciences (GILD) Watch with a composite score of 53/100 , based on 5 analysts with 40% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +6.92 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -13.08 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case. Value Analyst remains cautious — price-to-book of 6.7x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Dividend yield of 4.0% pays you to wait — Value
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Price structure making higher highs and higher lows — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • Price-to-book of 6.7x prices in significant intangible value — Value
  • ROE of only -16.3% -- cheap may mean cheap for a reason — Value
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
53/100
Agreement
40%
Analysts
5
Conviction
Contested
Sector Rank
Top 79%
of 192 Healthcare peers
Value Analyst bearish
30 / 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
+ Dividend yield of 4.0% pays you to wait
− Price-to-book of 6.7x prices in significant intangible value
Growth Analyst neutral
52 / 100 · High confidence
Moderate growth -- present but not remarkable
+ 5 consecutive earnings beats -- consistent execution
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst bullish
61 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 50.9 to 53.1.

Analyst-level changes:
  • Technical Analyst: stance neutral->bullish; score 48->61 (+13); +3 bullish signal(s).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
64.4
Neutral
MACD Histogram
-0.435
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$127.64
Resistance
$157.26
Bollinger %B
0.73
Inside Bands
Price vs Moving Averages
EMA 9
$147.91 Above
EMA 21
$147.79 Above
EMA 50
$144.72 Above
EMA 200
$135.43 Above

Fundamental Analysis

Valuation
67
Growth
40
Profitability
75
Financial Health
26
Cash Flow
70
Valuation
P/E Ratio -58.1×
P/B Ratio 15.89×
PEG Ratio 0.38
Dividend Yield 2.15%
52W High $157.29
52W Low $114.02
Quality & Growth
ROE 3748.6%
ROA 1441.8%
Gross Margin 7958.7%
Operating Margin -490.2%
Revenue Growth YoY —
Debt / Equity 2.22
AI Fundamental Assessment
P/E ratio of -58.1 (inexpensive relative to a 15-40x range); Price-to-book of 15.9x; PEG ratio of 0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 37.5%; Return on assets of 14.4%; Net margin of -10.6%; Gross margin of 79.6%; Current ratio of 1.27 (tight short-term liquidity); Debt-to-equity of 2.22; Free cash flow per share is positive (10.62); Most recent quarter beat estimates by 8.5%; 5 consecutive earnings beats; EPS growth decelerating (+9.1% -> -432.5% QoQ); Average YoY EPS growth of -435.8%; Analyst estimates falling over recent quarters
Get the Full GILD Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime